OPUS Registry for Patients Using Opsumit®

Trial Objective

The purpose of this study is to learn more about how Opsumit® (the commercial form of the medication macitentan) is used in clinical practice to treat pulmonary arterial hypertension (PAH) and other conditions. Our researchers also are collecting demographical, medical and safety information from patients treated with Opsumit®.

OPUS Registry for Patients Using Opsumit®


This trial is active and currently recruiting.

How to Participate

For more information, call 303.398.1172 or complete the form below.

Who Can Participate

Patients who are taking Opsumit® are eligible to participate.

Estimated Time Commitment

1 year

Over a period of at least one year, data will be collected from follow-up clinic visits and, if applicable, medical records. Participants’ doctors will manage their care no differently than if they were not part of the Opsumit® registry program. A medical history may be obtained by talking to the patient and/or reviewing medical records. From then on, medical data will be collected during routine visits to the doctor or potential hospital visits.

Trial Location

National Jewish Main Campus, Denver, CO



Trial Sponsors

Actelion Pharmaceuticals US, Inc.




Any Gender

Principal Investigators

Request More Information